ORA-TESTRYL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ORA-TESTRYL (ORA-TESTRYL).
Testosterone replacement therapy; binds to androgen receptors, promoting protein synthesis, muscle growth, and secondary sexual characteristic development.
| Metabolism | Metabolized in liver via CYP3A4 and CYP2C9 to androsterone, etiocholanolone, and 17-ketosteroids. |
| Excretion | Renal (90% as glucuronide and sulfate conjugates, 10% unchanged); Biliary/fecal (10%) |
| Half-life | Terminal half-life 2.5-3.5 hours; clinical context: requires multiple daily dosing to maintain steady-state levels |
| Protein binding | 97-99% bound to sex hormone-binding globulin (SHBG) and albumin |
| Volume of Distribution | 0.5-1.0 L/kg; indicates extensive tissue distribution, including reproductive tissues |
| Bioavailability | Oral: 3-6% (extensive first-pass metabolism); Buccal/sublingual: 20-40% |
| Onset of Action | Oral: 1-2 hours; Buccal/sublingual: 15-30 minutes |
| Duration of Action | Oral: 6-8 hours; Buccal/sublingual: 4-6 hours; clinical notes: duration shorter with sublingual route due to first-pass avoidance |
Intramuscular injection: 50-100 mg every 2-4 weeks.
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment required for renal impairment; use with caution if GFR <30 mL/min. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh class C). In moderate impairment (Child-Pugh class B), reduce dose by 50%. |
| Pediatric use | Not recommended in pediatric patients for androgen replacement; safety and efficacy not established. |
| Geriatric use | Use lowest effective dose (e.g., 50 mg IM every 4 weeks) due to increased risk of prostatic hypertrophy and cardiovascular events. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ORA-TESTRYL (ORA-TESTRYL).
| Breastfeeding | Excretion into breast milk is unknown. M/P ratio not established. Testosterone may suppress lactation and cause virilization of nursing infant. Discontinue breastfeeding or avoid drug. |
| Teratogenic Risk | Teratogenic risk profile: ORA-TESTRYL (testosterone undecanoate) is contraindicated in pregnancy. First trimester: virilization of female fetus; second and third trimesters: ongoing virilization, growth retardation. Class X. Transdermal testosterone has been associated with clitoromegaly, labial fusion, and urogenital sinus abnormalities in female fetuses. |
■ FDA Black Box Warning
Risk of blood clots, stroke, heart attack, and exacerbation of prostate cancer. Testosterone may be abused and cause serious health issues.
| Serious Effects |
Men with breast or prostate cancer, pregnant or breastfeeding women, hypersensitivity to testosterone, and patients with untreated sleep apnea.
| Precautions | Cardiovascular risk, polycythemia, benign prostatic hyperplasia, sleep apnea, and edema. Monitor hematocrit, lipids, and prostate-specific antigen. |
Loading safety data…
| Fetal Monitoring |
| If inadvertent exposure occurs, monitor fetal growth and anatomy via ultrasound. Assess for signs of virilization in female fetus. Monitor maternal blood pressure, liver function, lipid profile, and hematocrit. No specific fetal monitoring required if drug is avoided as recommended. |
| Fertility Effects | Testosterone suppresses endogenous gonadotropins, reducing spermatogenesis and potentially causing oligospermia or azoospermia. Reversible upon discontinuation. In females, may cause menstrual irregularities and anovulation. |